GLP-1 Therapies and Metabolic Health: Beyond Weight Loss
From semaglutide and tirzepatide to investigational molecules such as maridebart cafraglutide (MariTide), emerging treatments for obesity and diabetes raise a fundamental question: how can we better understand the metabolic changes that accompany weight loss?
GLP-1 therapies are transforming the management of obesity and diabetes
Glucagon-like peptide-1 (GLP-1) receptor agonists represent one of the most important therapeutic advances in recent years for treating type 2 diabetes and obesity.
They act on mechanisms involved in glucose-dependent insulin secretion, appetite and satiety. Their effects can lead to improved glycaemic control and substantial reductions in body weight.
However, their clinical relevance extends beyond the scale: research is also investigating their effects on cardiovascular health, kidney function and various metabolic pathways.
Different therapeutic strategies, one shared metabolic question
Treatments used for obesity and type 2 diabetes do not all work in the same way. Semaglutide and liraglutide are GLP-1 receptor agonists; tirzepatide activates both GIP and GLP-1 receptors. Their indications, effects and supporting clinical evidence depend on the medicine and the population studied.
New strategies are also being investigated, including maridebart cafraglutide (MariTide), which combines GLP-1 receptor agonism with GIP receptor antagonism and remains an investigational treatment.
These medicines require medical prescription and supervision. They should not be considered interchangeable alternatives.
Clinical benefits may extend beyond weight management
One of the most important advances has been demonstrating that certain therapies in this class can reduce cardiovascular events in specific populations.
In the SELECT trial, published in The New England Journal of Medicine, once-weekly semaglutide 2.4 mg was evaluated in 17,604 participants with overweight or obesity, established cardiovascular disease and no diabetes.
Relative Risk Reduction
Reduction in the primary composite cardiovascular endpoint compared with placebo.
Participants
People with established cardiovascular disease and overweight or obesity, without diabetes.
Heart attack, stroke and cardiovascular death
The primary endpoint included cardiovascular death, nonfatal myocardial infarction and nonfatal stroke.
These findings highlight the importance of evaluating clinically meaningful outcomes rather than focusing exclusively on body weight or biomarkers.
The evidence relates to semaglutide at the dose and in the population studied in SELECT; it should not automatically be extrapolated to every medicine in this class.
What happens to metabolism during these treatments?
Body weight and HbA1c are essential indicators, but they do not fully describe every metabolic process.
Weight loss may be accompanied by changes in lipid transport, energy substrate availability, certain inflammatory signals and amino acid metabolism.
In addition, some of the weight lost may be fat-free mass. Nutritional assessment, physical activity and body composition therefore remain important aspects of follow-up.
Lipid Metabolism
How do circulating lipids and lipoprotein characteristics evolve during treatment?
Energy Metabolism
What changes occur in glucose, ketone bodies and metabolites involved in energy utilisation?
Muscle Metabolism
How do amino acid signals and other markers associated with muscle metabolism evolve?
What can we learn by comparing pharmacological treatments and bariatric surgery?
Metabolomics makes it possible to investigate how the body changes after interventions that may lead to similar or different amounts of weight loss, and to what extent those metabolic responses overlap.
In a study by Angelidi and colleagues, published online in 2022 in Metabolism, researchers used NMR-based metabolomic profiling to investigate early changes during liraglutide treatment and after bariatric surgery. The research included two placebo-controlled liraglutide studies and a surgical cohort undergoing Roux-en-Y gastric bypass or sleeve gastrectomy.
Surgery was associated with greater weight loss and broader changes in several metabolic parameters. However, after adjusting for weight loss, many of the differences between interventions were attenuated. These findings show why metabolomic signatures should be interpreted alongside the magnitude of weight loss and the clinical context.
A 2026 editorial in Metabolites, entitled Metabolomics in Motion: Translating Molecular Signatures into Clinical Impact, also highlights research on liraglutide and metabolic surgery, placing it within the development of translational metabolomics and emphasising the need for standardisation and clinical validation.
A Question for Current Research
Can longitudinal metabolomic profiles help distinguish changes associated with weight loss from those related to the mechanism of each intervention?
What can MetBalance® contribute?
MetBalance® is a Biosfer Teslab solution based on nuclear magnetic resonance (NMR) spectroscopy that analyses lipoproteins, glycoproteins and low-molecular-weight metabolites from a blood sample.
Its approach integrates different metabolic signals into five dimensions, interpreted in the context of an individual's age and sex.
This provides an integrated view of metabolic health that complements the interpretation of individual laboratory measurements.
Cardiovascular Health
Lipid profile, atherogenic risk-related signals, small lipoprotein particles and HDL parameters.
Inflammation
GlycA and GlycB signals, related to inflammatory processes reflected in glycoproteins.
Energy Metabolism
Glucose, lactate, ketone bodies and amino acids associated with energy metabolism.
Muscle Mass
Amino acid signals and metabolites related to muscle metabolism. These are not a direct measurement of muscle mass.
Kidney Function
Creatinine as a complementary signal, whose interpretation also depends on hydration, diet and muscle mass.
From a metabolic snapshot to observing changes over time
Analysing samples using nuclear magnetic resonance (NMR) spectroscopy makes it possible to compare metabolic profiles obtained at different time points and study how they evolve over time.
In research, comparing baseline and follow-up samples makes it possible to study individual metabolic trajectories and relate them to body weight, body composition and clinical outcomes. The challenge is to determine which signals provide additional, reproducible and clinically useful information.
Establish the starting point
Characterise the initial metabolomic profile through NMR-based sample analysis.
Observe the evolution
Analyse follow-up samples using NMR and compare profiles obtained under equivalent conditions.
Integrate the information
Relate metabolic signals to clinical, nutritional and anthropometric changes.
Towards a more complete understanding of metabolic response
The new generation of obesity treatments raises questions that go beyond how many kilograms a person loses.
Understanding the heterogeneity of metabolic responses could contribute to the design of new research strategies and, if clinical utility is demonstrated, more personalised follow-up approaches.
Metabolomics offers tools to investigate this complexity. The next challenge is to identify which signals provide clinically relevant and reproducible information beyond conventional tools.
MetBalance®: putting metabolism into context
At Biosfer Teslab, we develop metabolic profiling solutions based on NMR and advanced data analysis.
MetBalance® brings together different dimensions of metabolic health in an integrated, contextualised assessment designed to support professional nutrition, wellness and prevention programmes.
In a rapidly evolving therapeutic landscape, the ability to observe metabolic changes over time creates opportunities for new research projects and collaborations.
How does metabolism change during obesity treatment?
At Biosfer Teslab, we combine metabolomic profiling and biomarker analysis to support longitudinal research projects. If you are studying responses to pharmacological or surgical interventions, let's explore how to characterise these metabolic changes.
Discover MetBalance® →Have a research project? Let's discuss potential collaborations.
Scientific References and Sources
- Angelidi AM, Kokkinos A, Sanoudou D, Connelly MA, Alexandrou A, Mingrone G, Mantzoros CS. Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity. Metabolism. Published online in 2022. DOI
- Kounatidis D, Mourouzis I. Metabolomics in Motion: Translating Molecular Signatures into Clinical Impact. Metabolites. 2026. DOI
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389:2221–2232. DOI
- European Medicines Agency. EU actions regarding GLP-1 receptor agonists.
- European Medicines Agency. Wegovy: European public assessment report.
- ClinicalTrials.gov. MARITIME-CV: clinical trial of maridebart cafraglutide.
- Biosfer Teslab. MetBalance®: product information.